Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Goodrich

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Journal of Medicinal Chemistry|January 21, 2014
Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b repliconsMakonen Belema, Van N Nguyen, Jeffrey L Romine, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 2013
HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologiesOmar D Lopez, Van N Nguyen, Denis R St Laurent, et al.
Journal of Medicinal Chemistry|April 12, 2013
HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activityDenis R St Laurent, Michael H Serrano-Wu, Makonen Belema, et al.
Journal of Medicinal Chemistry|February 14, 2014
Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvirMakonen Belema, Van N Nguyen, Carol Bachand, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervixYoung Kwang Chae, Megan Othus, Sandip P Patel, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Journal of Medicinal Chemistry|January 21, 2014
Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b repliconsMakonen Belema, Van N Nguyen, Jeffrey L Romine, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 2013
HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologiesOmar D Lopez, Van N Nguyen, Denis R St Laurent, et al.
Journal of Medicinal Chemistry|April 12, 2013
HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activityDenis R St Laurent, Michael H Serrano-Wu, Makonen Belema, et al.
Journal of Medicinal Chemistry|February 14, 2014
Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvirMakonen Belema, Van N Nguyen, Carol Bachand, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervixYoung Kwang Chae, Megan Othus, Sandip P Patel, et al.
Pageof 10